| pubmed-article:7670112 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7670112 | lifeskim:mentions | umls-concept:C0038250 | lld:lifeskim |
| pubmed-article:7670112 | lifeskim:mentions | umls-concept:C0005953 | lld:lifeskim |
| pubmed-article:7670112 | lifeskim:mentions | umls-concept:C0079460 | lld:lifeskim |
| pubmed-article:7670112 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:7670112 | lifeskim:mentions | umls-concept:C0431085 | lld:lifeskim |
| pubmed-article:7670112 | lifeskim:mentions | umls-concept:C0079189 | lld:lifeskim |
| pubmed-article:7670112 | lifeskim:mentions | umls-concept:C0205307 | lld:lifeskim |
| pubmed-article:7670112 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
| pubmed-article:7670112 | lifeskim:mentions | umls-concept:C1517333 | lld:lifeskim |
| pubmed-article:7670112 | lifeskim:mentions | umls-concept:C1171947 | lld:lifeskim |
| pubmed-article:7670112 | lifeskim:mentions | umls-concept:C0591833 | lld:lifeskim |
| pubmed-article:7670112 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:7670112 | pubmed:dateCreated | 1995-10-19 | lld:pubmed |
| pubmed-article:7670112 | pubmed:abstractText | A fusion protein was synthesized consisting of the murine granulocyte-macrophage colony-stimulating factor (mGM-CSF) gene spliced to a truncated form of the diphtheria toxin (DT390) gene coding for a molecule that retained full enzymatic activity, but excluded the native binding domain. The DT390-mGM-CSF hybrid gene was cloned into a vector under the control of an inducible promoter and the protein expressed in Escherichia coli. After induction, a protein was purified from inclusion bodies in accord with the deduced molecular weight of DT390 mGM-CSF. Cell-free studies of the adenosine diphosphate-ribosylating activity of DT390 mGM-CSF showed results that were similar to those of native DT. The DT390 mGM-CSF immunotoxin inhibited FDCP2.1d, a murine myelomonocytic tumor line expressing the GM-CSF receptor with an IC50 (concentration inhibiting 50% activity) of 5 x 10(-11) mol/L. The fusion toxin was specifically cytotoxic and directed by the GM-CSF portion of the molecule because addition of a monoclonal antibody directed against GM-CSF inhibited its ability to kill the cell line. Cell lines that do not express GM-CSF receptor were not inhibited by the fusion toxin. DT390 mGM-CSF was also able to specifically inhibit normal committed bone marrow (BM) progenitor cells as measured in clonal colony-forming unit granulocyte-macrophage assays. Together, these findings indicate that DT390 mGM-CSF may be useful as a novel tool for purging BM of contaminating leukemia cells or in vivo for eliminating residual leukemia cells. Also, it can be used to determine whether committed and/or noncommitted BM progenitor cells express the GM-CSF receptor. | lld:pubmed |
| pubmed-article:7670112 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7670112 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7670112 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7670112 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7670112 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:7670112 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7670112 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7670112 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7670112 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7670112 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7670112 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7670112 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:7670112 | pubmed:issn | 0006-4971 | lld:pubmed |
| pubmed-article:7670112 | pubmed:author | pubmed-author:ChanC HCH | lld:pubmed |
| pubmed-article:7670112 | pubmed:author | pubmed-author:ValleraD ADA | lld:pubmed |
| pubmed-article:7670112 | pubmed:author | pubmed-author:KreitmanR JRJ | lld:pubmed |
| pubmed-article:7670112 | pubmed:author | pubmed-author:BlazarB RBR | lld:pubmed |
| pubmed-article:7670112 | pubmed:author | pubmed-author:EideC RCR | lld:pubmed |
| pubmed-article:7670112 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7670112 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:7670112 | pubmed:volume | 86 | lld:pubmed |
| pubmed-article:7670112 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7670112 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7670112 | pubmed:pagination | 2732-40 | lld:pubmed |
| pubmed-article:7670112 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:7670112 | pubmed:meshHeading | pubmed-meshheading:7670112-... | lld:pubmed |
| pubmed-article:7670112 | pubmed:meshHeading | pubmed-meshheading:7670112-... | lld:pubmed |
| pubmed-article:7670112 | pubmed:meshHeading | pubmed-meshheading:7670112-... | lld:pubmed |
| pubmed-article:7670112 | pubmed:meshHeading | pubmed-meshheading:7670112-... | lld:pubmed |
| pubmed-article:7670112 | pubmed:meshHeading | pubmed-meshheading:7670112-... | lld:pubmed |
| pubmed-article:7670112 | pubmed:meshHeading | pubmed-meshheading:7670112-... | lld:pubmed |
| pubmed-article:7670112 | pubmed:meshHeading | pubmed-meshheading:7670112-... | lld:pubmed |
| pubmed-article:7670112 | pubmed:meshHeading | pubmed-meshheading:7670112-... | lld:pubmed |
| pubmed-article:7670112 | pubmed:meshHeading | pubmed-meshheading:7670112-... | lld:pubmed |
| pubmed-article:7670112 | pubmed:meshHeading | pubmed-meshheading:7670112-... | lld:pubmed |
| pubmed-article:7670112 | pubmed:meshHeading | pubmed-meshheading:7670112-... | lld:pubmed |
| pubmed-article:7670112 | pubmed:meshHeading | pubmed-meshheading:7670112-... | lld:pubmed |
| pubmed-article:7670112 | pubmed:meshHeading | pubmed-meshheading:7670112-... | lld:pubmed |
| pubmed-article:7670112 | pubmed:meshHeading | pubmed-meshheading:7670112-... | lld:pubmed |
| pubmed-article:7670112 | pubmed:meshHeading | pubmed-meshheading:7670112-... | lld:pubmed |
| pubmed-article:7670112 | pubmed:meshHeading | pubmed-meshheading:7670112-... | lld:pubmed |
| pubmed-article:7670112 | pubmed:meshHeading | pubmed-meshheading:7670112-... | lld:pubmed |
| pubmed-article:7670112 | pubmed:meshHeading | pubmed-meshheading:7670112-... | lld:pubmed |
| pubmed-article:7670112 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7670112 | pubmed:articleTitle | A murine cytokine fusion toxin specifically targeting the murine granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor on normal committed bone marrow progenitor cells and GM-CSF-dependent tumor cells. | lld:pubmed |
| pubmed-article:7670112 | pubmed:affiliation | Department of Therapeutic Radiology, University of Minnesota Hospital and Clinics, Minneapolis 55455, USA. | lld:pubmed |
| pubmed-article:7670112 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7670112 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:7670112 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
